THC reduced pain and enhanced a specific pain inhibition pathway in fibromyalgia patients | Research

The takeaway

In a small crossover trial, sublingual THC selectively enhanced one type of central pain modulation (offset analgesia) while having no effect on another (conditioned pain modulation).

Pain researchers, fibromyalgia clinicians, cannabinoid pharmacology specialists

Baseline offset analgesia predicted 40% of THC pain relief response

What the researchers found

THC (0.2 mg/kg sublingual) significantly reduced spontaneous pain ratings on the McGill scale compared to both baseline and placebo. THC also enhanced offset analgesia relative to placebo (P=0.008) but had no effect on conditioned pain modulation (P=0.27). Baseline offset analgesia magnitude predicted who would respond to THC treatment (R²=0.404, P=0.003).

Why it matters

This is the first study to test whether THC affects different central pain modulation mechanisms differently, finding that it selectively enhances offset analgesia. If baseline offset analgesia can predict who responds to THC, it could help match the right patients to cannabinoid therapy.

The numbers in context

n=23 fibromyalgia patients; THC vs placebo P=0.02 for pain reduction; offset analgesia enhancement P=0.008; baseline OA predicted response R²=0.404; no CPM effect P=0.27

How the study worked

Randomized, double-blind, placebo-controlled crossover design with 23 fibromyalgia patients. Each participant completed two sessions with McGill Pain Questionnaire, VAS assessments, and evaluations of offset analgesia and conditioned pain modulation before and after sublingual THC or placebo.

What this study cannot tell us

Very small sample (23 patients). Single-dose acute study does not reflect chronic use. Only tested one THC dose (0.2 mg/kg sublingual). No long-term safety or efficacy data.

How to read the evidence

Rigorous double-blind crossover RCT design is strong, but very small sample size (n=23) and single-dose protocol limit confidence in the findings.

When this study was published

2025 publication; trial registered as NCT05644054

The bigger picture

Fibromyalgia involves dysfunctional central pain processing, and treatments that restore normal pain inhibition pathways are a priority. This finding that THC selectively targets one pathway but not another suggests cannabinoids work through specific neural mechanisms rather than general pain suppression.

Questions still open

Would repeated THC dosing maintain offset analgesia enhancement over time? Can offset analgesia testing be used clinically to predict cannabinoid treatment response before prescribing?

Common questions

What is offset analgesia?

Offset analgesia is a pain inhibition response where a slight decrease in a painful stimulus produces a disproportionately large reduction in perceived pain. It reflects the brain's ability to actively suppress pain signals.

Could this help predict who benefits from THC for pain?

Possibly. Patients with greater baseline offset analgesia responded better to THC, suggesting this test could serve as a biomarker for personalizing cannabinoid therapy, though larger studies are needed.

Read the original research

The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia.

Journal of cannabis research, 7(1), 86

View on PubMed ↗Publisher’s paper ↗

Citation

Agbaria, Yara; Preger, Raz; Aloush, Valerie; Ablin, Jacob N; Sharon, Haggai; Jacob, Giris. (2025). The impact of tetrahydrocannabinol on central pain modulation in chronic pain: a randomized clinical comparative study of offset analgesia and conditioned pain modulation in fibromyalgia.. Journal of cannabis research, 7(1), 86. https://doi.org/10.1186/s42238-025-00348-x